Publication:
Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution

Simple item page
dc.contributor.coauthorOrtiz, Alberto
dc.contributor.coauthorSoler, Maria Jose
dc.contributor.departmentN/A
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.kuauthorMızrak, Berk
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileResearcher
dc.contributor.kuprofileUndergraduate Student
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid110580
dc.contributor.yokid368625
dc.contributor.yokidN/A
dc.date.accessioned2024-11-10T00:09:27Z
dc.date.issued2023
dc.description.abstractAcute kidney injury (AKI) is common in hospitalized patients while common risk factors for the development of AKI include postoperative settings, patients with baseline chronic kidney disease (CKD) or congestive heart failure. Intravenous (IV) fluid therapy is a crucial component of care for prevention and treatment of AKI. In this narrative review, we update the approach to IV fluid therapy in hospitalized patients including the timing of fluid prescription, and the choice of fluid type, amount and infusion rate along with the potential adverse effects of various crystalloid and colloid solutions, addressing specifically their use in patients with acute kidney disease, CKD or heart failure, and their potential impact on the risk of hospital-acquired AKI.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsorshipSanofi
dc.description.sponsorshipBoehringer-Ingelheim A.O. has received grants from Sanofi and consultancy or speaker fees or travel support from Advicciene, Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Alexion, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma, and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes. A.O. is the former Editor-in-Chief of CKJ. M.K. is member of the CKJ Editorial Board. M.J.S. reports honorarium for conferences, consulting fees, and advisory boards from AstraZeneca, Novo Nordsik, Esteve, Vifor, Bayer, Mundipharma, Ingelheim Lilly, Jansen, Fresenius, ICU Medical, Travere Ther-apeutics, and Boehringer. M.J.S. also has received grants from Boehringer-Ingelheim. M.J.S. is Editor-in-Chief of CKJ.
dc.identifier.doi10.1093/ckj/sfac270
dc.identifier.eissn2048-8513
dc.identifier.issn2048-8505
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85169892292
dc.identifier.urihttp://dx.doi.org/10.1093/ckj/sfac270
dc.identifier.urihttps://hdl.handle.net/20.500.14288/17133
dc.identifier.wos926209200001
dc.keywordsAcute kidney injury
dc.keywordsChronic kidney disease
dc.keywordsColloid solution
dc.keywordsCrystalloid solution
dc.keywordsIntravenous fluid therapy
dc.keywordsCritically-ill patients
dc.keywordsBalanced crystalloids
dc.keywordsHydroxyethyl starch
dc.keywordsAcid-base
dc.keywordsSaline
dc.keywordsResuscitation
dc.keywordsAlbumin
dc.keywordsDisease
dc.keywordsMetaanalysis
dc.keywordsRestriction
dc.languageEnglish
dc.publisherOxford University Press (OUP)
dc.sourceClinical Kidney Journal
dc.subjectUrology
dc.subjectNephrology
dc.titleIntravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
dc.typeReview
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.authorid0000-0003-0190-2746
local.contributor.authorid0000-0001-7995-4488
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorMızrak, Berk

Files

Collections

Publications without Fulltext